PHAR
Pharming Group N.V. NASDAQ Listed Dec 23, 2020$12.87
Mkt Cap $917.8M
52w Low $9.80
27.0% of range
52w High $21.18
50d MA $14.27
200d MA $15.66
P/E (TTM)
73.5x
EV/EBITDA
21.0x
P/B
3.3x
Debt/Equity
0.4x
ROE
—
P/FCF
18.6x
RSI (14)
60.60
ATR (14)
$0.47
Beta
0.12
50d MA
$14.27
200d MA
$15.66
Avg Volume
10.3K
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Darwinweg 24 · Leiden, P7 2333 CR · NL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | 0.15 | 0.07 | -53.3% | 15.14 | +0.0% | -4.2% | +6.3% | +0.4% | -1.5% | +1.4% | — |
| Nov 6, 2025 | AMC | 0.05 | 0.10 | +100.0% | 14.70 | +9.5% | +5.0% | +13.7% | -10.0% | +8.6% | +2.7% | — |
| Jul 31, 2025 | AMC | -0.10 | 0.06 | +160.0% | 11.11 | -3.6% | -1.4% | +11.8% | +1.9% | -1.5% | -1.1% | — |
| May 8, 2025 | AMC | -0.25 | -0.22 | +12.0% | 10.01 | +1.0% | +0.2% | -3.2% | +3.0% | -8.5% | -0.2% | — |
| Mar 13, 2025 | AMC | 0.07 | 0.05 | -28.6% | 8.74 | -0.9% | +2.4% | -1.7% | +0.0% | +1.5% | +0.0% | — |
| Oct 24, 2024 | AMC | 0.01 | -0.02 | -300.0% | 8.30 | +5.7% | +4.8% | +1.6% | -1.8% | +2.1% | +0.6% | — |
| Aug 1, 2024 | AMC | -0.00 | -0.01 | -400.0% | 7.63 | +1.2% | -5.0% | +4.6% | +6.7% | -2.3% | -0.6% | — |
| May 8, 2024 | AMC | 0.01 | -0.19 | -2000.0% | 9.50 | -1.8% | +2.0% | +3.2% | -6.6% | +3.1% | -0.4% | — |
| Mar 14, 2024 | AMC | 0.05 | -0.03 | -160.0% | 10.92 | +4.6% | +5.2% | +0.1% | -4.3% | +2.5% | -3.7% | — |
| Oct 26, 2023 | AMC | 0.13 | 0.05 | -61.5% | 10.92 | +6.1% | +1.4% | -1.5% | +8.8% | -0.7% | +1.9% | — |
| Aug 3, 2023 | AMC | -0.02 | 0.02 | +200.0% | 12.50 | +0.0% | +0.0% | -4.5% | +0.0% | +2.8% | +0.0% | — |
| May 11, 2023 | AMC | -0.01 | -0.17 | -1600.0% | 10.21 | +11.4% | +8.6% | +4.7% | +1.9% | -1.1% | +1.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.01 | $15.84 | -1.1% | -0.2% | +1.6% | +0.5% | +0.0% | -1.8% |
| Mar 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $15.14 | $15.14 | +0.0% | -4.2% | +6.3% | +0.4% | -1.5% | +1.4% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.93 | $8.67 | -2.9% | -1.0% | -0.1% | -1.2% | +0.7% | -1.5% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.93 | $8.93 | +0.0% | +0.0% | -1.0% | -0.1% | -1.2% | +0.7% |
| Mar 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.74 | $8.66 | -0.9% | +2.4% | -1.7% | +0.0% | +1.5% | +0.0% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.74 | $8.66 | -0.9% | +2.4% | -1.7% | +0.0% | +1.5% | +0.0% |
| Dec 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.89 | $8.90 | +0.1% | -1.0% | -3.5% | +5.3% | +1.8% | +14.6% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.98 | $8.91 | -0.8% | -1.0% | -1.0% | -3.5% | +5.3% | +1.8% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.74 | $9.59 | +9.7% | +6.1% | +0.5% | -3.6% | -1.0% | -1.0% |
| Oct 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.70 | $8.68 | -0.2% | +1.6% | -1.8% | +2.1% | +0.6% | -4.4% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.96 | $8.29 | -7.5% | -7.4% | +4.8% | +1.6% | -1.8% | +2.1% |
| Oct 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.51 | $8.77 | +3.1% | +2.2% | -0.2% | -0.8% | +6.4% | -2.7% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.65 | $8.63 | -0.2% | +1.5% | -3.2% | +0.1% | +2.2% | -0.2% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.70 | $7.94 | +3.1% | +4.3% | +5.7% | -2.8% | +4.1% | -5.7% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.33 | $8.21 | -1.4% | -8.4% | -5.0% | +4.6% | +6.7% | -2.3% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.93 | $8.88 | -0.6% | +2.5% | +1.0% | -5.3% | -12.2% | +13.7% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.11 | $11.06 | -0.5% | -1.7% | +5.2% | +0.1% | -4.3% | +2.5% |
| Mar 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.26 | $12.39 | +1.1% | +3.6% | +7.1% | -4.8% | +4.2% | -5.4% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.96 | $12.72 | -15.0% | -18.0% | +3.6% | +7.1% | -4.8% | +4.2% |
| Feb 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.08 | $11.15 | +0.6% | +12.4% | -5.2% | -0.5% | +0.9% | +3.2% |
| Feb 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.13 | $11.90 | -9.4% | -10.5% | -6.1% | +0.4% | +12.4% | -5.2% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 7
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Silverberg Bernstein Capital Management Llc | 44,747 | $745K | Reduced | Mar 2026 |
| 2 | Morgan Stanley | 15,400 | $272K | Added | Dec 2025 |
| 3 | Citadel Advisors Llc | 10,189 | $170K | Reduced | Mar 2026 |
| 4 | Eversource Wealth Advisors, Llc | 1,997 | $17K | Added | Mar 2026 |
| 5 | Bnp Paribas Financial Markets | 400 | $7K | Reduced | Mar 2026 |
| 6 | Stone House Investment Management, Llc | 79 | $1K | New | Mar 2026 |
| 7 | Cornerstone Financial Management Llc | 32 | $532 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Nasdaq Composite Index Fund | 2,093 | $34K | Feb 2026 |
| 2 | Old Westbury Small & Mid Cap Strategies Fund | 73,152 | $22K | Jan 2026 |
Valuation
Market Cap
$917.8M
Enterprise Value
$830.8M
P/E (TTM)
73.54x
Forward P/E
63.46x
PEG Ratio
-3.57x
P/B
3.31x
P/S
2.48x
P/FCF
18.61x
EV/EBITDA
21.05x
Shares Out
71.3M
Financials (TTM)
Revenue
$369.4M
Net Income
$12.3M
EBITDA
$39.5M
Free Cash Flow
$49.3M
Op Cash Flow
$50.1M
EPS Basic
$0.04
EPS Diluted
$0.17
EPS Forward
$0.20
Gross Margin
87.3%
Op Margin
6.3%
Net Margin
3.3%
Balance Sheet
Total Assets
$499.8M
Total Liab.
$222.8M
Total Equity
$277.0M
Cash
$179.8M
LT Debt
$92.7M
Book Value/Sh
$3.88
Debt/Equity
0.42x
Current Ratio
2.59
Quick Ratio
2.03
Returns & Growth
ROE
—
ROA
—
ROIC
1.0%
Rev Growth YoY
+26.9%
EPS Growth YoY
+123.5%
Price Returns
2W
+0.2%
1M
-21.4%
3M
-20.3%
6M
-25.8%
12M
+22.5%
Technicals
52W High
$21.18
52W Low
$9.80
50d MA
$14.27
200d MA
$15.66
RSI (14)
60.60
ATR (14)
$0.47
Beta
0.12
Avg Volume
10K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$38.67
High
$42.00
Low
$37.00
Median
$37.00
Data updated apr 26, 2026 7:32pm
· Source: financialmodelingprep.com